Avexa was a Biotechnology and Research Company formed in 2004 in Melbourne, Victoria. Specifically, Avexa discovered and developed anti-infective pharmaceutical medicines for the treatment of serious human infectious diseases.
Avexa’s research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by Human Immunodeficiency Virus (HIV) and Vancomycin- and methicillin-resistant bacteria, both areas of high medical need.
Avexa also made their debut on the ASX in 2004, at 28.5 cents per share, which was below it’s issue price of 30 cents per share.
Avexa’s Research Partners
Avexa have research partners in its HIV program, HBV programs and VRI program.
Avexa’s research partners in its HIV program include Victorian College of Pharmacy, Monash University, Centre for Drug Candidate Optimisation, Monash University, The University of Wollongong and The Shanghai Institute of Organic Chemistry.
Avexa’s research partners in its HBV program include Victorian College of Pharmacy, Centre for Drug Candidate Optimisation, Monash University, The University of Adelaide, The North Carolina State University, USA, Georgetown University, USA, Burnet Institute, Melbourne and The Shanghai Institute of Organic Chemistry.
Avexa’s research partners on its VRI program include Wollongong University, Victorian College of Pharmacy and Centre for Drug Candidate Optimisation, The Shanghai Institute of Organic Chemistry.
Avexa’s Business Development
Avexa’s commercial strategy is focused on realizing the value in internal projects in the area of anti-infectives by achieving definitive, well established milestones for each project.
Avexa has an extensive foundation of experience in anti-infective drug discovery and development and is keen to exploit its expertise through new collaborations in the anti-infectives area.
Avexa believes its expertise in drug development coupled with its passion to advance anti-infectives projects as effectively as possible make Avexa an excellent choice for projects in need of focused development.
In addition to their research partners, Avexa formed a large team which consisted of a board of directors, executive committee and a scientific advisory board.
Despite Avexa’s business development and improvement efforts, they announced their decision to end work in May 2010, due to the difficulty finding commercial partners for global licencing, legal protection concerns in the US market, and difficulty in confirming the drug effectiveness in certain patients.
Noop Business Improvement
Business improvement is crucial to long term growth. While the goal of efficiently delivering quality products and services is not new, it’s focus has shifted from being reactive to proactive while considering the impact on modern customer experience. Levering agile business analysis, a lean process outlook combined a design thinking approach presents a new era of opportunity for realising business potential.
Improving, innovating, defining and executing a strong and purposeful business protocol is the most effective means for gaining and sustaining an unfair competitive advantage.
Here at Noop, we are Perth’s agile business improvement consultants. We use a unique approach to transform your business, catalyse innovation, and accelerate profitable growth. Don’t just optimise, synergise. Learn more about our business improvement services here.